Market news

United Therapeutics' declines are real but they sit in ~32% of the business, tax-normalized earnings power is $1.05 billion. See why UTHR stock is a Buy now.

Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.

Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.

Liquidia Corporation recently reported that the U.S. Food and Drug Administration granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for treating Raynaud's phenomenon associated with systemic sclerosis, and the company expects to begin its Phase 2a RE-WARM dose-finding study in October 2026. This designation highlights a potential new use for an existing pulmonary arterial hypertension therapy in an area where no approved U.S. treatments currently exist, underscoring...

The U.S. Food and Drug Administration has granted Fast Track designation to Liquidia (LQDA) therapy YUTREPIA for Raynaud's phenomenon in systemic sclerosis, drawing investor attention to the stock and its rare disease pipeline. Liquidia’s latest Fast Track news lands after a sharp pullback, with the share price down about 22% over the past month and slightly weaker over the last week, even though the year to date share price return is 118.57% and the 1 year total shareholder return is...

Liquidia stock has delivered very strong long term gains over the past five years, yet current valuation checks present a more cautious picture that investors need to weigh carefully. After such a large move in the share price, the key issue is whether the recent performance and expectations around its pipeline are already fully reflected in what the market is paying today. Over the past five years, Liquidia has returned about 24x. This places a lot of weight on the company continuing to...

Detailed price information for Liquidia Corp (LQDA-Q) from The Globe and Mail including charting and trades.

Summers Value Partners, a boutique investment firm, noted in its Q2 2026 investor update that The Summers Value Fund delivered strong results in the quarter, returning 41.7% net, outperforming the Russell 2000 Index ETF (IWM), which returned 21.4%, and the Russell 2000 Value Index ETF (IWN), which returned 17.1%. The letter can be downloaded here. The Fund experienced […]

MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it will present two posters at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain. Dr. Rajeev Saggar, M.D., Chief Medical Officer of Liquidia, said: “These presentations represent impo

MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company’s business in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m. ET. Access to this event will be available on the “Investors” page of Liquidia’s website at https://liqui

Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.

Investors need to pay close attention to LQDA stock based on the movements in the options market lately.

Liquidia Corporation is rated Sell as YUTREPIA growth is slowing, valuation tops $6B, and the TPIP threat looms. Click for this LQDA stock update.

Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.

Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.

Detailed price information for Liquidia Corp (LQDA-Q) from The Globe and Mail including charting and trades.

Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, […]

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

It needed to post a blowout quarter instead of the good one it delivered.

Liquidia stock has delivered an extremely strong run over the past few years, yet the valuation checks now suggest investors are dealing with a mixed picture rather than a clear bargain or clear overvaluation. After such a sharp move, the recent pullback raises the question of how much of the good news is already reflected in the current price. Liquidia has returned about 28.7x over the last 5 years, which puts recent pricing under closer scrutiny for anyone considering fresh...

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

Detailed price information for Liquidia Corp (LQDA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Liquidia Corp (LQDA-Q) from The Globe and Mail including charting and trades.

Liquidia's YUTREPIA commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Read why LQDA stock is a Buy.

Moby summary of Liquidia Corporation's Q2 2026 earnings call

Liquidia topped second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits.

Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +5.71% and +3.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Corporation (NASDAQ:LQDA) shares fell 4. 58% in premarket trading on Wednesday after the biopharmaceutical company reported second-quarter earnings below Wall Street expectations, despite revenue coming in slightly ahead of forecasts.

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026Recorded fourth consecutive quarter of increasing profitability, with net income of $74.7 million, adjusted EBITDA of $96.3 million and an increase in cash and cash equivalents of $61.4 million compared to th

Detailed price information for Liquidia Corp (LQDA-Q) from The Globe and Mail including charting and trades.

MORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be avail